Objective To investigate whether or not the infusion of anti-SARS-CoV-2 antibody-positive stock plasma inducing the antibody-dependent enhancement(ADE)effect in the patients with COVID-19 complicating liver dysfunction.Methods The clinical data of 26 patients with COVID-19 complicating liver dysfunction infused with SARS-CoV-2 antibody-positive stock plasma in this hospital from December 15,2022 to January 20,2023 were analyzed retrospectively.The changes of peripheral blood mononuclear cells(MONO)count and cytokines IL-2,IL-4,IL-6,IL-10,TNF-α and IFN-γ levels were compared and analyzed before and after plasma infusion.Thirty-seven patients with COVID-19 without plasma infusion during the same period served as the control group.The situation such as peripheral blood MONO count,cytokines lev-els,throat swab SARS-CoV-2 nucleic acid test,pulmonary infection lesion absorption on 5 d of treatment were compared between the two groups.Results The proportions of peripheral blood MONO count increase in the observation group and control group were 69.23％and 59.56％respectively,the proportions of cytokines in-crease were 66.67％vs.76.92％for IL-2,22.22％vs.46.15％for IL-4,33.33％vs.38.46％for IL-6,33.33％vs.30.27％for IL-10,33.33％vs.46.15％for TNF-α and 44.44％vs.61.54％for IFN-γ,the throat swab SARS-CoV-2 nucleic acid detection negative ratio was 46.67％vs.59.09％.The proportion of the pa-tients with lesion absorption beginning was 87.50％vs.84.85％,and the differences were not statistically sig-nificant(P＞0.05).Conclusion Infusion of stock plasma containing anti-SARS-CoV-2 polyclonal antibodies in the patients with COVID-19 complicating liver dysfunction does not induce significant ADE.